Safety of immune checkpoint inhibitors in non-small-cell lung cancer patients with idiopathic interstitial pneumonia: a matched case–control study

PURPOSE: The immune checkpoint inhibitor nivolumab is commonly used for non-small-cell lung cancer treatment. Immune checkpoint inhibitors cause immune-related adverse events, including interstitial pneumonia. However, there are no studies on the risk factors for interstitial pneumonia exacerbation...

Descripción completa

Detalles Bibliográficos
Autores principales: Ichimura, Takenori, Hinata, Miwa, Ichikura, Daisuke, Suzuki, Shinya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8738498/
https://www.ncbi.nlm.nih.gov/pubmed/34648059
http://dx.doi.org/10.1007/s00280-021-04362-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8738498/
https://www.ncbi.nlm.nih.gov/pubmed/34648059
http://dx.doi.org/10.1007/s00280-021-04362-7

Ejemplares similares